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Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for
this condition. The objective of the study is to investigate the use of mycophenolate
mofetil (MMF) to treat scleroderma interstitial ILD.
We report a retrospective chart review of 17 patients with scleroderma ILD treated with
MMF (2 g/day) for at least 12 months. Demographics, bronchoalveolar lavage (BAL)
findings, pulmonary physiology and high-resolution computed tomography were recorded
at baseline and after 12 and 24 months of therapy.
Baseline BAL (n ¼ 12) showed alveolitis (median of 18% neutrophils). Ninety-four percent
of subjects had either improved or stable lung function after 12 months of treatment: four
improved, 12 were stable and only one worsened. All patients had radiographic
abnormalities consistent with ILD. After 12 months of therapy, radiological findings
(n ¼ 15) were stable in 11 patients, worse in three, and improved in one. There were no
side effects attributable to MMF therapy recorded.
Treatment of patients with scleroderma ILD for up to 24 months with MMF was generally
associated with stable pulmonary function. These data argue for a prospective trial using
MMF to treat scleroderma ILD.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Scleroderma (or systemic sclerosis, SSc) has a prevalence of
242 cases per million in the United States.1 The most
common pulmonary manifestations of SSc are interstitial
lung disease (ILD) and pulmonary arterial hypertension.2–4
The prevalence of ILD in patients with SSc varies from
70% to 90% depending on whether pulmonary function tests
or high-resolution computed tomography (HRCT) scans are
used to screen for the disease.5 ILD typically appears early in
the course of SSc 5 and, when untreated, tends to progress.6
It is currently the leading cause of death in patients
with SSc.7
A number of immunosuppressive agents have been used to
treat patients with SSc-ILD; the greatest experience is with
cyclophosphamide. A large prospective trial has been shown
to slow disease progression in a subset of patients.8
Recently, mycophenolate mofetil (MMF) has been used in a
limited number of patients.9,10 MMF is the prodrug of
mycophenolic acid, which acts to inhibit ‘‘de novo’’
synthesis of purine nucleotides. Because lymphocytes are
dependent on this pathway for DNA synthesis, MMF inhibits
their proliferation.11 The pathogenesis of SSc-ILD is com-
plex, and likely involves cytokines, growth factors, T and B
cells, activated alveolar macrophages, and fibroblasts,
which promote an inflammatory and pro-fibrotic environ-
ment.12–14 Because MMF inhibits many of these mediators
and pathways, we considered it to be a reasonable therapy
for SSc-ILD.9Methods
Following approval of this study by the Committee on Human
Research at the University of California San Francisco, the
medical records of patients with SSc referred to the ILD
Clinic at the University of California San Francisco between
2000 and 2005 were reviewed. Patients who fulfilled the
American College of Rheumatology criteria for the diagnosis
of SSc,15 had evidence of ILD by HRCT and received MMF
(2 g/day) were identified as study subjects.
Age, gender, dyspnea, cough, chest pain, symptoms of
gastroesophageal reflux disease, smoking status, type of SSc
(limited or diffuse), year of SSc diagnosis, and history of
previous treatment were recorded. Bronchoalveolar lavage
(BAL) was performed according to established protocol,16
with samples obtained from two locations: (1) the region
with the greatest HRCTabnormality and (2) a region with no
HRCT abnormality. ‘‘Alveolitis’’ was defined as the presence
of greater than or equal to 3% neutrophils or 2% eosinophils
on BAL cell count and differential.6,17,18
Forced vital capacity (FVC) and diffusing capacity for
carbon monoxide (DLCO) were measured using the standard
technique.19,20 Available pulmonary function tests were
abstracted at baseline, 12 and 24 months into therapy. We
categorized the response as improved (X10% increase),
stable or worse (X10% decrease) according to international
standards.21
Baseline and follow-up HRCT scans were reviewed by two
chest radiologists who were blinded to clinical and pulmon-
ary function data as well as the sequence studies were
performed (scans were randomly presented as study A or B).A consensus opinion was reached as to whether studies A and
B were the same or whether one was worse than the other.
Subsequent decoding of the order of the scans determined
whether there was improvement, stabilization or progres-
sion of ILD, which was defined by the presence of ground
glass opacities, reticulation, traction bronchiectasis and/or
honeycombing.
The CT was read as usual interstitial pneumonia (UIP)
pattern if the dominant abnormality were bilateral sub-
pleural reticulation with lower lobe predominance and
honeycombing, or as non-specific interstitial pneumonia
(NSIP) pattern when ground glass opacities, fine reticula-
tion, sparing the peripheral and the absence of honeycomb-
ing were the dominant radiographic pattern.
Evaluation for side effects: In general, patients were
questioned for symptomatic side effects related to myco-
phenolate every 3 months (e.g. rash, any infection,
diarrhea, gastrointestinal esophageal reflux disease or
abdominal pain), and complete blood count checked every
4–8 weeks to rule out anemia or leucopenia. Side effects
were recorded in the patient’s chart.
Continuous data are expressed as mean, median, stan-
dard deviation and maximum/minimum values; binary data
are expressed as percentages. Non-parametric methodology
was used given the skewed distribution of data points. The
primary comparison involved FVC and DLCO measurements
at initiation and after 12 months of therapy using the signed
rank test. A p value ofo0.05 was considered statistically
significant. Only subjects with longitudinal data (i.e. before
and after measurements) were included in the comparison
analyses. All statistical analysis was performed using SAS v
9.2 (Cary, NC).Results
Because of the lack of proven therapies for SSc-ILD and
intolerance to cyclophosphamide (the most widely used
therapy) by many of our patients, we began to consider
other therapeutic options for treating SSc-ILD. This report
summarizes our experience using MMF as first line therapy
for treating SSc-ILD. Eighty-four cases with SSc were
reviewed. Of these patients, 38 satisfied the inclusion
criteria for SSc-ILD and seventeen had been treated with
MMF for at least 12 months time. These 17 patients
constituted the study cohort (Tables 1 and 2). The average
age was 50.879.3 years, women outnumbered men (10–7),
most were non-smokers, and most suffered from diffuse
cutaneous SSc. SSc was diagnosed a median of 24 months
prior to starting MMF, and the median duration of lung
involvement was 12 months. All but two patients were
symptomatic and all symptomatic patients complained of
dyspnea. Thirteen had bibasilar end inspiratory crackles on
auscultation.
Twelve patients underwent bronchoscopy with BAL prior
to therapy. All had alveolitis, which was most intense in fluid
obtained from lung segments with ground glass attenuation
on HRCT (18% neutrophils and 6% eosinophils) compared to
fluid obtained from lung segments without ground glass
attenuation on HRCT (7% neutrophils and 1% eosinophils,
p ¼ 0.01, Figure 1). Interestingly, three of the four patients
who improved had the lowest percentage of neutrophils
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Table 1 Individual Patient Clinical, BAL and Treatment Data.
Patient
no.
Age
(y)/sex
Type
of SSc
Duration
of SSc
(months)
Duration
of ILD
(months)
BAL
alveolitis
Present/
Absent
Baseline
FVC %
predic-
ted
Baseline
DLCO %
predic-
ted
HRCT
pattern
Treatment
duration
(months)
Side
effects
Outcome
1. 48/M dcSSc 24 12 Present 53 35 UIP 24 None Stable
2. 50/M dcSSc 24 12 Present 51 27 UIP 12 None Stable
3. 32/M lcSSc 108 36 Present 100 78 NSIP 24 None Stable
4. 43/F dcSSc 12 12 Present 99 77 NR 24 None Stable
5. 62/F dcSSc 8 8 Not done 100 88 NSIP 24 None Stable
6. 62/M dcSSc 8 1 Present 65 55 NSIP 12 None Worse
7. 51/F dcSSc NR 36 Present 100 80 NSIP 12 None Improved
8. 46/F dcSSc 60 12 Present 35 30 NSIP 24 None Stable
9. 65/M dcSSc 96 6 Present 97 56 NSIP 12 None Improved
10. 55/M dcSSc 12 12 Present 69 27 NR 24 None Improved
11. 39/F dcSSc 24 24 Present 89 64 NSIP 24 None Stable
12. 40/F dcSSc 100 12 Not done 83 51 UIP 24 None Improved
13. 47/F lcSSc 96 60 Not done 63 46 NSIP 12 None Stable
14. 60/F dcSSc NR 12 Present 42 30 UIP 12 None Stable
15. 59/F dcSSc 24 24 Not done 67 35 NSIP 12 None Stable
16. 58/M dcSSc 100 36 Present 48 62 NSIP 12 None Stable
17. 47/F dcSSc 24 24 Not done 62 35 NSIP 12 None Stable
Definition of abbreviations: NR ¼ not recorded; BAL ¼ bronchoalveolar lavage; FVC ¼ forced vital capacity; DLCO ¼ diffusion capacity
for carbon monoxide; SSc ¼ scleroderma; dcSSc ¼ diffuse cutaneous scleroderma; lcSSc ¼ limited cutaneous scleroderma;
ILD ¼ interstitial lung disease.
A.C. Zamora et al.152(3%, 9%, and 13%). The fourth patient did not have a BAL
performed.
To determine whether therapy with MMF was associated
with changes in pulmonary physiology, we computed the
change in FVC and DLCO % predicted following 12 and 24
months of therapy. Of 17 patients completing 12 months
of MMF therapy, their median change in FVC and DLCO
% predicted showed no statistically significant change
from baseline (Table 3). On average, the FVC and DLCO
(% predicted) increased by 2.6% (p ¼ 0.22) and 1.4%
(p ¼ 0.74), respectively.
Eight patients completed 24 months of follow-up. Similar
to their 12-month follow-up, their median change in FVC and
DLCO % predicted showed no statistically significant change
from baseline (Table 3). Similarly, on average, the FVC and
DLCO % of predicted increased by 2.4% (p ¼ 0.57) and 2%
(p ¼ 0.84), respectively. We categorically evaluated the
pulmonary function changes of individual patients following
12 months of therapy. By this analysis, we found four
subjects (24%) were improved, 12 (70%) remained stable,
and one (6%) worsened (Figure 2).
HRCT images were available in 15 patients. In these
patients, the HRCT findings improved in one patient (7%),
remained stable in 11 patients (73%), and progressed in
three (20%) (Figure 3). The single improved HRCTwas due to
a reduction in the extent of ground glass opacities. The
worsening of HRCT’s was due to a slight increase in extent of
reticular opacities. However, these radiographic changes
were subtle as there were no overall change in formal
radiologic scores for any individual patient.
In general, patients were screened for side effects every
3 months. No side effects were recorded for any of the
patients.Discussion
ILD is central to the prognosis of patients with SSc.
Currently, there is no definitive treatment for this disorder.
Our retrospective review of 17 patients with SSc-ILD and
evidence of alveolitis treated with MMF shows that the
majority had stable pulmonary function and radiographic
abnormalities on HRCT following 12 months of therapy.
Similar findings were seen in a subgroup that completed
24 months of treatment.
Patients with SSc and alveolitis have been shown to suffer
deterioration in lung function and increased mortality
compared with SSc patients without alveolitis.6,17,18 All
patients in our cohort who had a BAL had alveolitis,
suggesting they were a population more likely to have
progressive loss of lung function in the absence of
treatment.6 No significant progression in FVC and/or DLCO
% predicted was found in these patients either after 12 or
24 months of follow-up, and pulmonary function improved
more commonly in patients than those in whom it worsened.
Finally, by HRCT most patients remained stable. These
observations suggest that MMF therapy may slow the
progression of SSc-ILD.
The presence of ground glass opacities on HRCTcorrelated
with an intense alveolitis by BAL. BAL fluid obtained
from regions of lung that were ‘‘normal’’ by HRCT also
had alveolitis, although less severe. In agreement with
findings of Clements et al.,22 these results indicate that
while ground glass opacities on HRCT are indicative of
alveolitis, ‘‘early’’, low-grade alveolitis can be present by
BAL when it is not evident by HRCT. Therefore, in some
instances, the BAL may be more sensitive than HRCT for
detecting alveolitis.
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Table 2 Baseline demographic characteristics, clinical
features, and pulmonary function test results.
Variable Value*
Age in years 50.8 (9.3)
50 (32, 65)
Gender: Female/Male 10/7
Type of scleroderma
Diffuse 15 (88)
Limited 2 (12)
Smoking
Former smokers 5 (29)
Never smokers 12 (73)
Symptoms (percent of subjects)
Asymptomatic 2 (11)
Dyspnea 15 (88)
Cough 10 (58)
Chest Pain 1 (6)
Physical finding
Inspiratory crackles 12 (71)
Clubbing 0 (0)
Pulmonary function testing
FVC % predicted 72 (22)
67 (35, 100)
DLCO % predicted 50 (20)
49 (27, 88)
*Continuous data are presented as mean (standard devia-
tion), median (minimum, maximum). Dichotomous data are
presented as number (percent of total).
Definition of abbreviations: FVC ¼ forced vital capacity;
DLCO ¼ diffusion capacity for carbon monoxide.
Figure 1 Bronchoalveolar lavage cell differentials. Cell differ-
entials were determined on BAL fluid obtained from regions of
lung with ground glass opacities (black circle) and without
ground glass opacities (open circle) on HRCT scan. In each
group, the horizontal bar represents the median percentage
of cells on the differential. Mono ¼ mononuclear cells; Neut ¼
neutrophils, Lymph ¼ lymphocytes, Eo ¼ eosinophils.
Table 3 Changes in pulmonary function test values.
N Value* P value
FVC % predicted
Change from
Baseline—12 months
17 2.6 (7.8) 0.22
1.0 (14, 13)
Change from
Baseline—24 months
8 2.4 (11.7) 0.57
4.5 (15, 16)
DLCO % predicted
Change from
Baseline—12 months
17 1.4 (13.5) 0.65
1.0 (31, 38)
Change from
Baseline—24 months
8 2.0 (14.16) 0.84
0.5 (18, 29)
* Values expressed as mean (standard deviation), median
(minimum, maximum).
Definition of abbreviations: FVC ¼ forced vital capacity;
DLCO ¼ diffusion capacity for carbon monoxide.
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as there is no proven therapy with a favorable side effect
profile.23 Recently, the Scleroderma Lung Study8 compared
the efficacy of oral cyclophosphamide to placebo. The mean
absolute difference in adjusted 12-month FVC percent
predicted between the cyclophosphamide and placebo
groups was 2.53%, favoring cyclophosphamide. Adverse
events like hematuria, leucopenia and pneumonia were
more frequent in cyclophosphamide treated patients. Thus,
while cyclophosphamide appears to have a modest bene-
ficial effect for treating SSc-ILD, it may come at the expense
of severe side effects and in the opinion of some, it should
not yet be consider the routine therapy for these patients.24
Recently, a pilot study summarizing the use of MMF in
SSc-ILD patients suggested it may be effective.9 However,
the sample size was small (n ¼ 5) and follow-up was only 6
months. Similarly, Swigris and coworkers performed a
retrospective observational study of 28 patients with ILD
and connective tissue disease (nine patients had SSc-ILD)
treated with MMF.10 They showed that values for FVC, TLC,
and DLCO remained stable. Most had failed previous
glucocorticoid or immunomodulatory therapy and the
majority of patients in this study received prednisone in
addition to MMF; therefore, it is difficult to determine the
beneficial effects of either medication individually.
In our study, MMF was well tolerated and no patient had
adverse effects attributable to the medication. Although
side effects are more common when higher (4 3g/d) doses
of MMF are used.25 Few side effects were found when 2 g/d
of mycophenolate was used to treat diffuse SSc26 or lupus
nephritis.25,27 Additionally, MMF has little ovarian toxicity28
and it may prevent pneumocystis carinii pneumonia (PCP).29
Thus, MMF appears to have a more favorable side effect
profile than cyclophosphamide and therefore may be better
tolerated in SSc-ILD patients.
Our study is limited by its retrospective design, small
sample size and lack of controls. A larger, prospective,
placebo-controlled trial is required to prove the efficacy of
MMF. Safety data in our study was not prospectively
collected and we relied on retrospective chart review. The
occurrence of mild or transient adverse effects may be
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Figure 2 Individual changes in lung function from baseline to 12
and 24 months following treatment with mycophenolate mofetil.
(A) Forced capacity vital (FVC, % of predicted), (B) diffusion
capacity for carbon monoxide (DLCO, % of predicted), and
(C) summary of the outcome of patients who had either
improved, stable, or worse lung function over 12 months.
Figure 3 Outcome of HRCT following 12 months of mycophe-
nolate mofetil treatment.
A.C. Zamora et al.154underestimated. Finally, our patient population consists of
patients referred to a tertiary care center and may not
represent the general population of SSc-ILD seen in the
community setting.In conclusion, these data suggest that MMF is a safe
and well-tolerated therapy for SSc-ILD and that it may slow
the course of respiratory decline. Larger, prospective,
controlled trials are needed to prove efficacy of MMF in
SSc-ILD.
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